glp 1 hypertension Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control A study of 42,000 adults
Description
GIP/GLP-1/GCGR, triple glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonist
*Retatrutide is a novel medication that acts on GLP1, GIP, and Glucagon receptors
The standard protocol already accounts for this by starting at 2.5 mg and increasing every four weeks, but for some people, even 2.5 mg hits too hard
The Bottom Line It is obvious that these medications represent a significant advance in weight loss treatment
doi: 10.2337/db07-0697
